Exenatide Dose-escalation 417 the glucagon-like peptide 1-(7–36)- amide receptor of insulin- secreting β-cells. JB i o lC h e m 1993; 268: 19 650–19 655. 9. Hardman JG, Limbird LE. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics (10th edn). McGraw-Hill: New York, 2001. 10. Cox DR, Oakes D. Analysis of Survival Data . Chapman & Hall: New York, 1984. 11. G ¨oke B, Herrmann-Rinke C. The evolving role of α-glucosidase inhibitors. Diabetes Metab Rev 1998; 14: S31–S38. 12. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303. 13. Mertes G. Safety and efﬁcacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193–204.14. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755–772. 15. Catalan VS, Couture JA, LeLorier J. Predictors of persistence of use of the novel antidiabetic agent acarbose. Arch Intern Med 2001; 161: 1106–1112.